Summary: A single high dose of psilocybin produces more than a temporary psychedelic experience — it alters brain function and anatomy for at least a month. New research reports a rapid rise in “brain entropy” (greater diversity of neural activity) during the acute effects, and links that entropic state to next‑day psychological insight and to measurable improvements in well‑being and cognitive flexibility a month later.
The study, conducted by teams at UC San Francisco and Imperial College London and published in Nature Communications, examined healthy volunteers with no prior psychedelic exposure. Using EEG, fMRI and diffusion tensor imaging (DTI), the researchers tracked brain changes from the acute dose through one month after a single 25 mg administration of psilocybin.
Key Facts
- Rapid entropy increase: Within an hour of a 25 mg dose, EEG recordings revealed a substantial increase in cortical signal entropy, indicating more diverse and less stereotyped patterns of neural activity.
- Entropy predicts insight: The magnitude of this entropic surge predicted how much emotional self‑awareness and psychological insight participants reported the next day.
- Anatomical changes: One month later, DTI showed greater organization and integrity of neural tracts in prefrontal‑subcortical pathways — a pattern opposite to the diffusion seen with normal aging.
- Loosening rigid patterns: Psilocybin appeared to reduce entrenched patterns of brain activity and thought, producing measurable gains in cognitive flexibility at one month.
- The experience matters: The researchers conclude that the subjective psychedelic experience — the “trip” and the insight it produces — is a central component of the drug’s therapeutic impact, not merely an incidental side effect.
In this controlled, within‑subject study, 28 psychedelic‑naive adults first received a very low 1 mg dose (treated as a placebo), underwent baseline and acute EEG monitoring, and completed standard measures of insight, well‑being and cognitive function. After several weeks, the same participants received 25 mg of psilocybin while researchers again recorded EEG during the acute phase and repeated psychological and imaging assessments up to one month later. This design allowed the team to compare placebo‑level responses to the effects of a full psychedelic dose within the same individuals.
What changed during and after dosing
EEG showed increased cortical signal entropy within the first one to two hours after the 25 mg dose, reflecting richer, less predictable neural signaling. Participants overwhelmingly rated the 25 mg session as one of the most unusual states of consciousness they had experienced. The next day, many reported heightened psychological insight and emotional clarity.
At one month, DTI scans revealed decreased axial diffusivity in prefrontal‑subcortical tracts, interpreted as greater tract density and integrity. These structural changes correlated with concurrent decreases in network modularity measured by fMRI, and participants demonstrated improved scores on standardized measures of well‑being and on tasks assessing cognitive flexibility.
Importantly, none of these effects were observed following the 1 mg dose. The pattern of results suggests a chain of influence: acute increases in brain entropy support next‑day psychological insight, and that insight in turn predicts improved well‑being and cognitive flexibility one month later.
Clinical and scientific implications
These findings provide converging electrophysiological, functional and anatomical evidence that a single high dose of psilocybin can induce persistent changes in brain structure and subjective experience. The results support the idea that the qualitative experience of the psychedelic state — characterized by elevated entropy and the potential for new perspectives or “aha” moments — is mechanistically important for lasting therapeutic benefits.
For clinical use, the study suggests dosing should aim not only for safety but for the neurophysiological conditions that foster insight. Measuring acute brain entropy could eventually help tailor dose and therapeutic support to maximize beneficial outcomes in conditions such as depression, anxiety and addiction. However, the authors emphasize that more research is needed to understand mechanisms and to translate these findings into clinical practice.
Study authors and funding
The paper’s senior author is Robin Carhart‑Harris, PhD (UCSF). Other contributors include researchers from UCSF and Imperial College London. The work received philanthropic funding to the Centre for Psychedelic Research at Imperial College London, the Alex Mosley Charitable Trust, the Beckley Foundation, and philanthropic support linked to Neuroscape and the Psychedelics Division at UCSF.
Key Questions Answered:
A: Brain entropy refers to the diversity and unpredictability of neural signals. Higher entropy indicates more varied communication across brain regions rather than rigid, repetitive patterns. In this study, elevated entropy correlated with psychological insight and later improvements in well‑being, suggesting that a more flexible neural state may help break the loops that maintain mood disorders.
A: DTI measures water diffusion along white matter tracts. The study found decreased axial diffusivity in certain tracts one month after psilocybin, which the authors interpret as greater organization or density of those pathways. While the exact cellular mechanisms remain to be clarified, the imaging changes indicate a physical alteration in brain wiring following the experience.
A: In this sample, the amount of improvement in well‑being tracked closely with the degree of reported insight. The study suggests that without an entropic state leading to psychological insight, long‑term benefits may be reduced. However, individual responses vary, and further research is needed to define predictors of therapeutic outcome.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- The journal paper was reviewed in full for accuracy.
- Additional explanatory context was added by staff writers.
About this neuroscience and psychedelics research news
Author: Levi Gadye
Source: UCSF
Contact: Levi Gadye – UCSF
Image credit: Neuroscience News
Original Research: Open access. “Human brain changes after first psilocybin use” by T. Lyons and colleagues. Published in Nature Communications. DOI: 10.1038/s41467-026-71962-3
Abstract
Human brain changes after first psilocybin use
Psychedelics substantially alter acute brain function and can change long‑term behavior, but durable anatomical and functional brain changes after a single use were not well established. In this exploratory, placebo‑controlled, within‑subjects EEG and MRI study of 28 healthy, psychedelic‑naive participants, a single high dose (25 mg) of psilocybin produced measurable anatomical and functional brain changes from one hour to one month post‑dose. Participants showed increased psychological insight, cognitive flexibility and well‑being at one month. DTI indicated changes in prefrontal‑subcortical tracts that correlated with reductions in network modularity. Increased EEG entropy at one to two hours post‑dose predicted improved well‑being at one month, with next‑day insight mediating this relationship. Effects were specific to the 25 mg dose; no comparable effects followed the 1 mg dose.